The DOI matches its Crossref record; the references it cites are not checked yet.
Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Open accessPreprint — published as 10.1158/2159-8290.cd-22-0405 · Paper page
Abstract
Generation of acquired resistance PDX model
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Resistance signals to KRAS G12C inhibitors can be overcome by the combined use of anti-EGFR antibody drug.
“Resistance signals to KRAS G12C inhibitors can be overcome by the combined use of anti-EGFR antibody drug (8, 9).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [9]
Metadata
- Authors
- Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., Perez, A. C., Chadalavada, K., Tse, E., Chowdhry, S., Bowker, S., Chang, Q., Qeriqi, B., Weigelt, B., Nanjangud, G. J., Berger, M. F., Der-Torossian, H., Anderes, K., Socci, N. D., Shia, J., Riely, G. J., Murciano-Goroff, Y. R., Li, B. T., Christensen, J. G., Reis-Filho, J. S., Solit, D. B., de Stanchina, E., Lowe, S. W., Rosen, N., & Misale, S.
- ORCID
- Yaeger, Rona
- Mezzadra, Riccardo
- Sinopoli, Jenna
- Bian, Yu
- Marasco, Michelangelo
- Kaplun, Esther
- Gao, Yijun
- Zhao, HuiYong
- Paula, Arnaud Da Cruz
- Zhu, Yingjie
- Perez, Almudena Chaves
- Chadalavada, Kalyani
- Tse, Edison
- Chowdhry, Sudhir
- Bowker, Sydney
- Chang, Qing
- Qeriqi, Besnik
- Weigelt, Britta
- Nanjangud, Gouri J.
- Berger, Michael F.
- Der-Torossian, Hirak
- Anderes, Kenna
- Socci, Nicholas D.
- Shia, Jinru
- Riely, Gregory J.
- Murciano-Goroff, Yonina R.
- Li, Bob T.
- Christensen, James G.
- Reis-Filho, Jorge S.
- Solit, David B.
- de Stanchina, Elisa
- Lowe, Scott W.
- Rosen, Neal
- Misale, Sandra
- Published
- 2023-04-04
- OpenAlex
- W4362553362
- Cited by
- 0
- References
- 0
- Type
- supplementary materials
- Language
- en
- Open access
- gold
- dx.doi.org
- Locations
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- acquired drug resistance, KRAS G12C, EGFR inhibition, colorectal cancer, patient-derived xenografts, molecular characterization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
